Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 200

1.

19q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes.

Aziz D, Etemadmoghadam D, Caldon CE, Au-Yeung G, Deng N, Hutchinson R; Australian Ovarian Cancer Study Group, Bowtell D, Waring P.

Gynecol Oncol. 2018 Sep 9. pii: S0090-8258(18)31169-7. doi: 10.1016/j.ygyno.2018.08.039. [Epub ahead of print]

PMID:
30209015
2.

PI3K activation in neural stem cells drives tumorigenesis which can be ameliorated by targeting the cAMP response element binding protein.

Daniel PM, Filiz G, Brown DV, Christie M, Waring PM, Zhang Y, Haynes JM, Pouton C, Flanagan D, Vincan E, Johns TG, Montgomery K, Phillips WA, Mantamadiotis T.

Neuro Oncol. 2018 Sep 3;20(10):1344-1355. doi: 10.1093/neuonc/noy068.

PMID:
29718345
3.

Exploring the feasibility and utility of exome-scale tumour sequencing in a clinical setting.

Lee B, Tran B, Hsu AL, Taylor GR, Fox SB, Fellowes A, Marquis R, Mooi J, Desai J, Doig K, Ekert P, Gaff C, Herath D, Hamilton A, James P, Roberts A, Snyder R, Waring P, McArthur G.

Intern Med J. 2018 Jul;48(7):786-794. doi: 10.1111/imj.13806.

PMID:
29607586
4.

Identification of Pik3ca Mutation as a Genetic Driver of Prostate Cancer That Cooperates with Pten Loss to Accelerate Progression and Castration-Resistant Growth.

Pearson HB, Li J, Meniel VS, Fennell CM, Waring P, Montgomery KG, Rebello RJ, Macpherson AA, Koushyar S, Furic L, Cullinane C, Clarkson RW, Smalley MJ, Simpson KJ, Phesse TJ, Shepherd PR, Humbert PO, Sansom OJ, Phillips WA.

Cancer Discov. 2018 Jun;8(6):764-779. doi: 10.1158/2159-8290.CD-17-0867. Epub 2018 Mar 26.

PMID:
29581176
5.

Loss of NF-κB1 Causes Gastric Cancer with Aberrant Inflammation and Expression of Immune Checkpoint Regulators in a STAT-1-Dependent Manner.

O'Reilly LA, Putoczki TL, Mielke LA, Low JT, Lin A, Preaudet A, Herold MJ, Yaprianto K, Tai L, Kueh A, Pacini G, Ferrero RL, Gugasyan R, Hu Y, Christie M, Wilcox S, Grumont R, Griffin MDW, O'Connor L, Smyth GK, Ernst M, Waring P, Gerondakis S, Strasser A.

Immunity. 2018 Mar 20;48(3):570-583.e8. doi: 10.1016/j.immuni.2018.03.003.

PMID:
29562203
6.

Optimizing Amplification of the GC-Rich TERT Promoter Region Using 7-Deaza-dGTP for Droplet Digital PCR Quantification of TERT Promoter Mutations.

Colebatch AJ, Witkowski T, Waring PM, McArthur GA, Wong SQ, Dobrovic A.

Clin Chem. 2018 Apr;64(4):745-747. doi: 10.1373/clinchem.2017.284257. Epub 2018 Jan 30. No abstract available.

PMID:
29382647
7.

An evaluation of the challenges to developing tumor BRCA1 and BRCA2 testing methodologies for clinical practice.

Ellison G, Ahdesmäki M, Luke S, Waring PM, Wallace A, Wright R, Röthlisberger B, Ludin K, Merkelbach-Bruse S, Heydt C, Ligtenberg MJL, Mensenkamp AR, de Castro DG, Jones T, Vivancos A, Kondrashova O, Pauwels P, Weyn C, Hahnen E, Hauke J, Soong R, Lai Z, Dougherty B, Carr TH, Johnson J, Mills J, Barrett JC.

Hum Mutat. 2018 Mar;39(3):394-405. doi: 10.1002/humu.23375. Epub 2017 Dec 28.

8.

Prognostic value of MACC1 and proficient mismatch repair status for recurrence risk prediction in stage II colon cancer patients: the BIOGRID studies.

Rohr UP, Herrmann P, Ilm K, Zhang H, Lohmann S, Reiser A, Muranyi A, Smith J, Burock S, Osterland M, Leith K, Singh S, Brunhoeber P, Bowermaster R, Tie J, Christie M, Wong HL, Waring P, Shanmugam K, Gibbs P, Stein U.

Ann Oncol. 2017 Aug 1;28(8):1869-1875. doi: 10.1093/annonc/mdx207.

PMID:
28460000
9.

Intratumorous heterogeneity for RAS mutations in a treatment-naïve colorectal tumour.

Lunke S, Lee B, Kranz S, Gibbs P, Waring P, Christie M.

J Clin Pathol. 2017 Aug;70(8):720-723. doi: 10.1136/jclinpath-2017-204327. Epub 2017 Mar 17.

PMID:
28314739
10.

Examining the impact of regular aspirin use and PIK3CA mutations on survival in stage 2 colon cancer.

Murphy C, Turner N, Wong HL, Sinnathamby M, Tie J, Lee B, Desai J, Skinner I, Christie M, Hutchinson R, Lunke S, Waring P, Gibbs P, Tran B.

Intern Med J. 2017 Jan;47(1):88-98. doi: 10.1111/imj.13312.

PMID:
27800646
11.

Immunomodulation by MYB is associated with tumor relapse in patients with early stage colorectal cancer.

Millen R, Malaterre J, Cross RS, Carpinteri S, Desai J, Tran B, Darcy P, Gibbs P, Sieber O, Zeps N, Waring P, Fox S, Pereira L, Ramsay RG.

Oncoimmunology. 2016 Jun 29;5(7):e1149667. doi: 10.1080/2162402X.2016.1149667. eCollection 2016 Jul.

12.

A community-based model of rapid autopsy in end-stage cancer patients.

Alsop K, Thorne H, Sandhu S, Hamilton A, Mintoff C, Christie E, Spruyt O, Williams S, McNally O, Mileshkin L, Ananda S, Hallo J, Loi S, Scott C, Savas P, Devereux L, O'Brien P, Gunawardena S, Hampson C, Strachan K, Jaravaza RD, Francis V, Young G, Ranson D, Samaranayake R, Stevens D, Boyle S, Fedele C, Topp M, Ho G, Teo ZL, Taylor RA, Papargiris MM, Lawrence MG, Wang H, Risbridger GP, Haynes NM, Medon M, Johnstone RW, Vidacs E, Arnau GM, Vergara IA, Papenfuss AT, McArthur G, Waring P, Carvosso S, Angel C, Gyorki D, Solomon B, Mitchell G, Shanley S, Francis PA, Dawson SJ, Haffenden A, Tidball E, Volchek M, Pyman J, Madadin M, Leditschke J, Cordner S; Melbourne Melanoma Project; Australian Ovarian Cancer Study Group (AOCS); Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), Shackleton M, Bowtell DD.

Nat Biotechnol. 2016 Oct;34(10):1010-1014. doi: 10.1038/nbt.3674. Epub 2016 Sep 12. No abstract available.

PMID:
27617737
13.

Clustered somatic mutations are frequent in transcription factor binding motifs within proximal promoter regions in melanoma and other cutaneous malignancies.

Colebatch AJ, Di Stefano L, Wong SQ, Hannan RD, Waring PM, Dobrovic A, McArthur GA, Papenfuss AT.

Oncotarget. 2016 Oct 11;7(41):66569-66585. doi: 10.18632/oncotarget.11892.

14.

ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours.

Segelov E, Waring P, Desai J, Wilson K, Gebski V, Thavaneswaran S, Elez E, Underhill C, Pavlakis N, Chantrill L, Nott L, Jefford M, Khasraw M, Day F, Wasan H, Ciardiello F, Karapetis C, Joubert W, van Hazel G, Haydon A, Price T, Tejpar S, Tebbutt N, Shapiro J.

BMC Cancer. 2016 May 31;16:339. doi: 10.1186/s12885-016-2389-8.

15.

Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study.

Segelov E, Thavaneswaran S, Waring PM, Desai J, Robledo KP, Gebski VJ, Elez E, Nott LM, Karapetis CS, Lunke S, Chantrill LA, Pavlakis N, Khasraw M, Underhill C, Ciardiello F, Jefford M, Wasan H, Haydon A, Price TJ, van Hazel G, Wilson K, Simes J, Shapiro JD.

J Clin Oncol. 2016 Jul 1;34(19):2258-64. doi: 10.1200/JCO.2015.65.6843. Epub 2016 Apr 25.

PMID:
27114605
16.

Girdin (GIV) Expression as a Prognostic Marker of Recurrence in Mismatch Repair-Proficient Stage II Colon Cancer.

Ghosh P, Tie J, Muranyi A, Singh S, Brunhoeber P, Leith K, Bowermaster R, Liao Z, Zhu Y, LaFleur B, Tran B, Desai J, Jones I, Croxford M, Jover R, Goel A, Waring P, Hu S, Teichgraber V, Rohr UP, Ridder R, Shanmugam K, Gibbs P.

Clin Cancer Res. 2016 Jul 15;22(14):3488-98. doi: 10.1158/1078-0432.CCR-15-2290. Epub 2016 Mar 30.

17.

RAS Mutations as Predictive Biomarkers in Clinical Management of Metastatic Colorectal Cancer.

Waring P, Tie J, Maru D, Karapetis CS.

Clin Colorectal Cancer. 2016 Jun;15(2):95-103. doi: 10.1016/j.clcc.2015.10.006. Epub 2015 Nov 11. Review.

PMID:
26952655
18.

Stomach-Specific Activation of Oncogenic KRAS and STAT3-Dependent Inflammation Cooperatively Promote Gastric Tumorigenesis in a Preclinical Model.

Thiem S, Eissmann MF, Elzer J, Jonas A, Putoczki TL, Poh A, Nguyen P, Preaudet A, Flanagan D, Vincan E, Waring P, Buchert M, Jarnicki A, Ernst M.

Cancer Res. 2016 Apr 15;76(8):2277-87. doi: 10.1158/0008-5472.CAN-15-3089. Epub 2016 Feb 2.

19.

High-Throughput Amplicon-Based Copy Number Detection of 11 Genes in Formalin-Fixed Paraffin-Embedded Ovarian Tumour Samples by MLPA-Seq.

Kondrashova O, Love CJ, Lunke S, Hsu AL; Australian Ovarian Cancer Study (AOCS) Group, Waring PM, Taylor GR.

PLoS One. 2015 Nov 16;10(11):e0143006. doi: 10.1371/journal.pone.0143006. eCollection 2015.

20.

Corrigendum: Whole-genome characterization of chemoresistant ovarian cancer.

Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey PJ, Kassahn KS, Newell F, Quinn MC, Kazakoff S, Quek K, Wilhelm-Benartzi C, Curry E, Leong HS; Australian Ovarian Cancer Study Group, Hamilton A, Mileshkin L, Au-Yeung G, Kennedy C, Hung J, Chiew YE, Harnett P, Friedlander M, Quinn M, Pyman J, Cordner S, O'Brien P, Leditschke J, Young G, Strachan K, Waring P, Azar W, Mitchell C, Traficante N, Hendley J, Thorne H, Shackleton M, Miller DK, Arnau GM, Tothill RW, Holloway TP, Semple T, Harliwong I, Nourse C, Nourbakhsh E, Manning S, Idrisoglu S, Bruxner TJ, Christ AN, Poudel B, Holmes O, Anderson M, Leonard C, Lonie A, Hall N, Wood S, Taylor DF, Xu Q, Fink JL, Waddell N, Drapkin R, Stronach E, Gabra H, Brown R, Jewell A, Nagaraj SH, Markham E, Wilson PJ, Ellul J, McNally O, Doyle MA, Vedururu R, Stewart C, Lengyel E, Pearson JV, Waddell N, deFazio A, Grimmond SM, Bowtell DD.

Nature. 2015 Nov 19;527(7578):398. doi: 10.1038/nature15716. Epub 2015 Oct 21. No abstract available.

PMID:
26503049
21.

Intestinal-specific activatable Myb initiates colon tumorigenesis in mice.

Malaterre J, Pereira L, Putoczki T, Millen R, Paquet-Fifield S, Germann M, Liu J, Cheasley D, Sampurno S, Stacker SA, Achen MG, Ward RL, Waring P, Mantamadiotis T, Ernst M, Ramsay RG.

Oncogene. 2016 May 12;35(19):2475-84. doi: 10.1038/onc.2015.305. Epub 2015 Aug 24.

22.

Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer.

Karapetis CS, Maru D, Waring P, Tie J, Michael MZ.

Expert Rev Mol Diagn. 2015;15(8):1033-48. doi: 10.1586/14737159.2015.1052797. Epub 2015 Jul 12. Review.

PMID:
26166616
23.

Whole-genome characterization of chemoresistant ovarian cancer.

Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey PJ, Kassahn KS, Newell F, Quinn MC, Kazakoff S, Quek K, Wilhelm-Benartzi C, Curry E, Leong HS; Australian Ovarian Cancer Study Group, Hamilton A, Mileshkin L, Au-Yeung G, Kennedy C, Hung J, Chiew YE, Harnett P, Friedlander M, Quinn M, Pyman J, Cordner S, O'Brien P, Leditschke J, Young G, Strachan K, Waring P, Azar W, Mitchell C, Traficante N, Hendley J, Thorne H, Shackleton M, Miller DK, Arnau GM, Tothill RW, Holloway TP, Semple T, Harliwong I, Nourse C, Nourbakhsh E, Manning S, Idrisoglu S, Bruxner TJ, Christ AN, Poudel B, Holmes O, Anderson M, Leonard C, Lonie A, Hall N, Wood S, Taylor DF, Xu Q, Fink JL, Waddell N, Drapkin R, Stronach E, Gabra H, Brown R, Jewell A, Nagaraj SH, Markham E, Wilson PJ, Ellul J, McNally O, Doyle MA, Vedururu R, Stewart C, Lengyel E, Pearson JV, Waddell N, deFazio A, Grimmond SM, Bowtell DD.

Nature. 2015 May 28;521(7553):489-94. doi: 10.1038/nature14410. Erratum in: Nature. 2015 Nov 19;527(7578):398.

PMID:
26017449
24.

Temporal patterns in Saturnidae (silk moth) and Sphingidae (hawk moth) assemblages in protected forests of central Uganda.

Akite P, Telford RJ, Waring P, Akol AM, Vandvik V.

Ecol Evol. 2015 Apr;5(8):1746-57. doi: 10.1002/ece3.1477. Epub 2015 Mar 25.

25.

Equivocal ALK fluorescence in-situ hybridization (FISH) cases may benefit from ancillary ALK FISH probe testing.

Selinger C, Cooper W, Lum T, McNeil C, Morey A, Waring P, Amanuel B, Millward M, Peverall J, Van Vliet C, Christie M, Tran Y, Diakos C, Pavlakis N, Gill AJ, O'Toole S.

Histopathology. 2015 Nov;67(5):654-63. doi: 10.1111/his.12708. Epub 2015 May 24.

PMID:
25847523
26.

Applicability of next generation sequencing technology in microsatellite instability testing.

Gan C, Love C, Beshay V, Macrae F, Fox S, Waring P, Taylor G.

Genes (Basel). 2015 Feb 12;6(1):46-59. doi: 10.3390/genes6010046.

27.

AmpliVar: mutation detection in high-throughput sequence from amplicon-based libraries.

Hsu AL, Kondrashova O, Lunke S, Love CJ, Meldrum C, Marquis-Nicholson R, Corboy G, Pham K, Wakefield M, Waring PM, Taylor GR.

Hum Mutat. 2015 Apr;36(4):411-8. doi: 10.1002/humu.22763. Epub 2015 Mar 16.

PMID:
25664426
28.

Ubiquitous expression of the Pik3caH1047R mutation promotes hypoglycemia, hypoinsulinemia, and organomegaly.

Kinross KM, Montgomery KG, Mangiafico SP, Hare LM, Kleinschmidt M, Bywater MJ, Poulton IJ, Vrahnas C, Henneicke H, Malaterre J, Waring PM, Cullinane C, Sims NA, McArthur GA, Andrikopoulos S, Phillips WA.

FASEB J. 2015 Apr;29(4):1426-34. doi: 10.1096/fj.14-262782. Epub 2014 Dec 30.

PMID:
25550458
29.

EGFR mutation testing practices within the Asia Pacific region: results of a multicenter diagnostic survey.

Yatabe Y, Kerr KM, Utomo A, Rajadurai P, Tran VK, Du X, Chou TY, Enriquez ML, Lee GK, Iqbal J, Shuangshoti S, Chung JH, Hagiwara K, Liang Z, Normanno N, Park K, Toyooka S, Tsai CM, Waring P, Zhang L, McCormack R, Ratcliffe M, Itoh Y, Sugeno M, Mok T.

J Thorac Oncol. 2015 Mar;10(3):438-45. doi: 10.1097/JTO.0000000000000422.

30.

Loss of c-REL but not NF-κB2 prevents autoimmune disease driven by FasL mutation.

O'Reilly LA, Hughes P, Lin A, Waring P, Siebenlist U, Jain R, Gray DH, Gerondakis S, Strasser A.

Cell Death Differ. 2015 May;22(5):767-78. doi: 10.1038/cdd.2014.168. Epub 2014 Oct 31.

31.

Sensitivity of blood lipids to changes in adiposity, exercise, and diet in children.

Telford RD, Cunningham RB, Waring P, Telford RM, Potter JM, Hickman PE, Abhayaratna WP.

Med Sci Sports Exerc. 2015 May;47(5):974-82. doi: 10.1249/MSS.0000000000000493.

PMID:
25202843
32.

Immunohistochemistry with the anti-BRAF V600E (VE1) antibody: impact of pre-analytical conditions and concordance with DNA sequencing in colorectal and papillary thyroid carcinoma.

Dvorak K, Aggeler B, Palting J, McKelvie P, Ruszkiewicz A, Waring P.

Pathology. 2014 Oct;46(6):509-17. doi: 10.1097/PAT.0000000000000119.

33.

Plasmacytomagenesis in Eμ-v-abl transgenic mice is accelerated when apoptosis is restrained.

Vandenberg CJ, Waring P, Strasser A, Cory S.

Blood. 2014 Aug 14;124(7):1099-109. doi: 10.1182/blood-2014-04-570770. Epub 2014 Jul 1.

34.

A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer.

Day F, Muranyi A, Singh S, Shanmugam K, Williams D, Byrne D, Pham K, Palmieri M, Tie J, Grogan T, Gibbs P, Sieber O, Waring P, Desai J.

Target Oncol. 2015 Mar;10(1):99-109. doi: 10.1007/s11523-014-0319-8. Epub 2014 May 27.

35.

KRAS mutation testing of metastatic colorectal cancer in Australia: where are we at?

Scott RJ, Fox SB, Desai J, Grieu F, Amanuel B, Garrett K, Harraway J, Cheetham G, Pattle N, Haddad A, Byron K, Rudzki B, Waring P, Iacopetta B.

Asia Pac J Clin Oncol. 2014 Sep;10(3):261-5. doi: 10.1111/ajco.12201. Epub 2014 May 9.

PMID:
24811330
36.

Therapeutic inhibition of Jak activity inhibits progression of gastrointestinal tumors in mice.

Stuart E, Buchert M, Putoczki T, Thiem S, Farid R, Elzer J, Huszar D, Waring PM, Phesse TJ, Ernst M.

Mol Cancer Ther. 2014 Feb;13(2):468-74. doi: 10.1158/1535-7163.MCT-13-0583-T. Epub 2014 Jan 7.

37.

Physiological expression of the PI3K-activating mutation Pik3ca(H1047R) combines with Apc loss to promote development of invasive intestinal adenocarcinomas in mice.

Hare LM, Phesse TJ, Waring PM, Montgomery KG, Kinross KM, Mills K, Roh V, Heath JK, Ramsay RG, Ernst M, Phillips WA.

Biochem J. 2014 Mar 1;458(2):251-8. doi: 10.1042/BJ20131412.

PMID:
24320611
38.

The prognostic significance of the BRAF V600E mutation in papillary thyroid carcinoma detected by mutation-specific immunohistochemistry.

McKelvie PA, Chan F, Yu Y, Waring P, Gresshoff I, Farrell S, Williams RA.

Pathology. 2013 Dec;45(7):637-44. doi: 10.1097/PAT.0000000000000008.

PMID:
24247620
39.

Physical education and blood lipid concentrations in children: the LOOK randomized cluster trial.

Telford RD, Cunningham RB, Waring P, Telford RM, Olive LS, Abhayaratna WP.

PLoS One. 2013 Oct 25;8(10):e76124. doi: 10.1371/journal.pone.0076124. eCollection 2013.

40.

Towards the introduction of the 'Immunoscore' in the classification of malignant tumours.

Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A, Bifulco C, Nagtegaal ID, Palmqvist R, Masucci GV, Botti G, Tatangelo F, Delrio P, Maio M, Laghi L, Grizzi F, Asslaber M, D'Arrigo C, Vidal-Vanaclocha F, Zavadova E, Chouchane L, Ohashi PS, Hafezi-Bakhtiari S, Wouters BG, Roehrl M, Nguyen L, Kawakami Y, Hazama S, Okuno K, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Wang Y, Kopetz S, Sinicrope FA, Scripcariu V, Ascierto PA, Marincola FM, Fox BA, Pagès F.

J Pathol. 2014 Jan;232(2):199-209. doi: 10.1002/path.4287. Review.

41.

Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancer.

Etemadmoghadam D, Au-Yeung G, Wall M, Mitchell C, Kansara M, Loehrer E, Batzios C, George J, Ftouni S, Weir BA, Carter S, Gresshoff I, Mileshkin L, Rischin D, Hahn WC, Waring PM, Getz G, Cullinane C, Campbell LJ, Bowtell DD.

Clin Cancer Res. 2013 Nov 1;19(21):5960-71. doi: 10.1158/1078-0432.CCR-13-1337. Epub 2013 Sep 4.

42.

Characterisation of apoptosis in myb-transformed hematopoietic cell (MTHC-A) lines: TNF-α-induced apoptosis and prevention by cAMP.

Sorimachi K, Waring P, Hapel AJ, Fukasawa I, Kaneko Y, Masawa N.

J Clin Exp Hematop. 2013;53(2):115-20.

43.

Proapoptotic Bak and Bax guard against fatal systemic and organ-specific autoimmune disease.

Mason KD, Lin A, Robb L, Josefsson EC, Henley KJ, Gray DH, Kile BT, Roberts AW, Strasser A, Huang DC, Waring P, O'Reilly LA.

Proc Natl Acad Sci U S A. 2013 Feb 12;110(7):2599-604. doi: 10.1073/pnas.1215097110. Epub 2013 Jan 24.

44.

Cancer classification using the Immunoscore: a worldwide task force.

Galon J, Pagès F, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G, Tatangelo F, Britten CM, Kreiter S, Chouchane L, Delrio P, Arndt H, Asslaber M, Maio M, Masucci GV, Mihm M, Vidal-Vanaclocha F, Allison JP, Gnjatic S, Hakansson L, Huber C, Singh-Jasuja H, Ottensmeier C, Zwierzina H, Laghi L, Grizzi F, Ohashi PS, Shaw PA, Clarke BA, Wouters BG, Kawakami Y, Hazama S, Okuno K, Wang E, O'Donnell-Tormey J, Lagorce C, Pawelec G, Nishimura MI, Hawkins R, Lapointe R, Lundqvist A, Khleif SN, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Palmqvist R, Nagtegaal ID, Wang Y, D'Arrigo C, Kopetz S, Sinicrope FA, Trinchieri G, Gajewski TF, Ascierto PA, Fox BA.

J Transl Med. 2012 Oct 3;10:205. doi: 10.1186/1479-5876-10-205. Review.

45.

Mutation detection by clonal sequencing of PCR amplicons and grouped read typing is applicable to clinical diagnostics.

Chambers PA, Stead LF, Morgan JE, Carr IM, Sutton KM, Watson CM, Crowe V, Dickinson H, Roberts P, Mulatero C, Seymour M, Markham AF, Waring PM, Quirke P, Taylor GR.

Hum Mutat. 2013 Jan;34(1):248-54. doi: 10.1002/humu.22207. Epub 2012 Oct 11.

PMID:
22915446
46.

Menin and p53 have non-synergistic effects on tumorigenesis in mice.

Loffler KA, Mould AW, Waring PM, Hayward NK, Kay GF.

BMC Cancer. 2012 Jun 18;12:252. doi: 10.1186/1471-2407-12-252.

47.

Physiological levels of Pik3ca(H1047R) mutation in the mouse mammary gland results in ductal hyperplasia and formation of ERα-positive tumors.

Tikoo A, Roh V, Montgomery KG, Ivetac I, Waring P, Pelzer R, Hare L, Shackleton M, Humbert P, Phillips WA.

PLoS One. 2012;7(5):e36924. doi: 10.1371/journal.pone.0036924. Epub 2012 May 30.

48.

SNP-based arrays complement classic cytogenetics in the detection of chromosomal aberrations in Wilms' tumor.

Zin R, Pham K, Ashleigh M, Ravine D, Waring P, Charles A.

Cancer Genet. 2012 Mar;205(3):80-93. doi: 10.1016/j.cancergen.2011.12.003.

PMID:
22469507
49.

An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice.

Kinross KM, Montgomery KG, Kleinschmidt M, Waring P, Ivetac I, Tikoo A, Saad M, Hare L, Roh V, Mantamadiotis T, Sheppard KE, Ryland GL, Campbell IG, Gorringe KL, Christensen JG, Cullinane C, Hicks RJ, Pearson RB, Johnstone RW, McArthur GA, Phillips WA.

J Clin Invest. 2012 Feb;122(2):553-7. doi: 10.1172/JCI59309. Epub 2012 Jan 3.

50.

Using tumour pathology to identify people at high genetic risk of breast and colorectal cancers.

Hopper JL, Jenkins MA, Dowty JG, Dite GS, Apicella C, Keogh L, Win AK, Young JP, Buchanan D, Walsh MD, Rosty C, Baglietto L, Severi G, Phillips KA, Wong EM, Dobrovic A, Waring P, Winship I, Ramus SJ, Giles GG, Southey MC.

Pathology. 2012 Feb;44(2):89-98. doi: 10.1097/PAT.0b013e32834e8e5b. Review.

PMID:
22198256

Supplemental Content

Loading ...
Support Center